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Ryanodine receptors (RyRs) are channels governing
the release of Ca2+ from the sarcoplasmic or endo-
plasmic reticulum. They are required for the contrac-
tion of both skeletal (RyR1) and cardiac (RyR2)
muscles. Mutations in both RyR1 and RyR2 have
been associated with severe genetic disorders, but
high-resolution data describing the disease variants
in detail have been lacking. Here we present the
crystal structures of the N-terminal domains of both
RyR2 (1–217) and RyR1 (9–205) at 2.55 A˚ and 2.9 A˚,
respectively. The domains map in a hot spot region
for disease mutations. Both structures consist of a
core beta trefoil domain flanked by an alpha helix.
Crystal structures of two RyR2 disease mutants,
A77V (2.2 A˚) and V186M (1.7 A˚), show that the muta-
tions cause distinct local changes in the surface of
the protein. A RyR2 deletion mutant causes signifi-
cant changes in the thermal stability. The disease
positions highlight two putative binding interfaces
required for normal RyR function.
INTRODUCTION
Excitation-contraction (E-C) coupling in skeletal muscle and
cardiac myocytes requires the release of Ca2+ into the cyto-
plasm. Ryanodine receptors (RyRs) are large (2.2 MDa)
membrane proteins that mediate the release of Ca2+ from the
sarcoplasmic or endoplasmic reticulum. Three different isoforms
(RyR1–3) have been identified in mammalian organisms. RyR1
predominates in skeletal muscle, whereas RyR2 regulates Ca2+
release in cardiac myocytes (Giannini et al., 1995). Each intact
RyR is a homotetramer built up by polypeptides of >5000 amino
acids each. In addition, many auxiliary proteins associate with
the channels and regulate their activity (Bers, 2004; Zalk et al.,
2007).
In skeletal muscle, mutations in RyR1 are known to lead to
malignant hyperthermia (MH) and central core disease (CCD)
(Robinson et al., 2006), whereas the cardiac RyR2 mutations
have been associated with two forms of cardiac arrhythmia—
catecholaminergic polymorphic ventricular tachycardia (CPVT)
and arrhythmogenic right ventricular dysplasia type 2 (ARVD2)
(George et al., 2007; Thomas et al., 2007). The mutations wereStructure 17, 1505–15originally found to be clustered in three distinct regions, giving
rise to mutational ‘‘hot spots’’ in the N-terminal region (1–
600), a central domain (2100–2500), and the C-terminal
channel region (3800–5000). Sequence alignment of RyR1
and RyR2 shows that the hot spots are matching (Yano, 2008),
although mutations in RYR1 are increasingly found outside the
original hot spots (Robinson et al., 2006). Some mutations
even occur in both isoforms, suggesting that RyR1 and RyR2
share similar mechanisms.
High-quality electronmicroscopy (EM) experiments have shed
light on the 3D structure of RyRs, especially for RyR1 (Ludtke
et al., 2005; Samso et al., 2005). The bulk of the RyR structure
is located in the cytoplasm, with only 10% forming the trans-
membrane and channel pore regions. EM images of RyR2 and
RyR3 show a similar overall structure, although some differences
exist in the corners of the cytoplasmic portion (Liu et al., 2001;
Sharma et al., 1998; Wang et al., 2007). Many distinct blobs
are present in the EM structures, suggesting that the RyR protein
is built up by individual domains. However, atomic resolution
information has only recently become available (Amador et al.,
2009; Maximciuc et al., 2006; Wright et al., 2008). The limited
availability of high-resolution information has hampered a
detailed understanding of RyR function in physiological and
diseased states.
Here we describe crystal structures for the N-terminal
domains of RyR1 and RyR2. This domain is located in the
N-terminal mutation hot spot. We also solved the crystal struc-
tures of two RyR2 disease mutants, putting us in the unique
position to look at the effect of diseasemutations on a eukaryotic
ion channel at high resolution. The mutations highlight distinct
interaction interfaces on the surface of the RyR2 N-terminal
domain. Two flexible cysteine pairs seem to be poised to
undergo oxidation or receive modifications.
RESULTS
Overall Structure of the RyR2 N-Terminal Domain
We solved the crystal structure of the N-terminal domain (NTD) of
mouse RyR2 (residues 1–217) at 2.55 A˚ resolution (Figures 1A
and 1B and Table 1). The crystal structure contains two chains
in the asymmetric unit. All structural analysis given below is
performed with the slightly more complete chain B. Central in
the NTD structure is a b-trefoil core, consisting of 12 b strands,
which is held together through extensive hydrophobic packing.
The N-terminal 11 residues form a flexible stretch with no14, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1505
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Structures of the RyR1 and RyR2 N-Terminal Domainsinterpretable electron density. The core is flanked by a 10-
residue a helix that is inserted between strands b4 and b5. In
addition, a small three-residue 310 helix is present in the loop
connecting b3 and b4.
The a helix packs against the b-trefoil core, burying a total of
640 A˚2 of solvent accessible surface area. The major interac-
tion is formed by L78 on the helix andW159 on the core, two resi-
dues that are conserved between the three RyR isoforms.
Although the helix is pointing away from the trefoil core, the
extensive packing suggests that its relative position is fixed.
A long loop connects the a helix back to b5. Although elec-
tron density is present for this loop, it is not of sufficient quality
to build a reliable model for this region, suggesting that the loop
has a high degree of flexibility (see Figures S1B and S1C avail-
able online). The exception is a single tryptophan residue
(W98), which packs in a hydrophobic pocket, lined by the
conserved L78 and W159 residues, next to the a helix (Fig-
ure 1A; Figure S1B) (see Experimental Procedures). This trypto-
RyR2     1  MADAGEG-EDEIQFLRTDDEVVLQCTATIHKEQQKLCLAAEGFGNRLCFLESTSNSKNVPPDLSICTFVLEQSLSVRALQ 79
RyR3     1  MAEGGEGGEDEIQFLRTEDEVVLQCIATIHKEQRKFCLAAEGLGNRLCFLEPTSEAKYIPPDLCVCNFVLEQSLSVRALQ 80
RyR1     1  MGDGGEG-EDEVQFLRTDDEVVLQCSATVLKEQLKLCLAAEGFGNRLCFLEPTSNAQNVPPDLAICCFTLEQSLSVRALQ 79
RyR2    80  EMLANTVEKSEGQVDVEKWKFMMKTAQGGGHRTLLYGHAILLRHSYSGMYLCCLSTSRSSTDKLAFDVGLQEDTTGEACW 159
RyR3    81  EMLANTGENGG-----------EGAAQGGGHRTLLYGHAVLLRHSFSGMYLTCLTTSRSQTDKLAFDVGLREHATGEACW 149
RyR1    80  EMLANTVEAG------------VESSQGGGHRTLLYGHAILLRHAHSRMYLSCLTTSRSMTDKLAFDVGLQEDATGEACW 147
RyR2   160  WTIHPASKQRSEGEKVRVGDDLILVSVSSERYLHLSYGNSSWHVDAAFQQTLWSVAPI 217
RyR3   150  WTIHPASKQRSEGEKVRIGDDLILVSVSSERYLHLSVSNGNIQVDASFMQTLWNVHPT 207
RyR1   148  WTMHPASKQRSEGEKVRVGDDLILVSVSSERYLHLSTASGELQVDASFMQTLWNMNPI 205
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Figure 1. Overall Structure of the RyR NTD
(A) Overall fold of the RyR2 NTD, showing the
a helix (a1) and 310 helix (310h1) in red, b strands
in blue, and loops in white. Two views are shown
(labeled ‘‘front’’ and ‘‘back’’), rotated 180 around
a vertical axis. All b strands are labeled for refer-
ence. Loops present in the construct but not
modeled are shown as dotted lines. W98 in the
a1-b5 loop is shown in stick representation. The
positions of the amino- and carboxytermini are
indicated.
(B) Sequence alignment of the NTD of mouse
RyR2, rabbit RyR1, and human RyR3. Conserved
residues are highlighted in gray. Secondary struc-
ture elements are shown on top (RyR2) and at the
bottom (RyR1). Sequence stretches present in the
constructs but not modeled in the electron density
are shown as dotted lines. Positions found in
disease mutations are marked with an asterisk
and highlighted in red.
(C) Superposition of the backbone trace of RyR1
(green) and RyR2 NTD (blue). Loops with confor-
mational changes are highlighted. The view is the
same as the front view of Figure 1A.
phan residue, and the loop to which it
belongs, are unique to RyR2.
RyR1 Versus RyR2
Are the structural features in the RyR2
NTD conserved among different RyR
isoforms? To answer this question, we
solved the structure of the rabbit RyR1
NTD (residues 9–205) to 2.9 A˚ resolution.
The RyR1 NTD structure contains nine
molecules in the asymmetric unit.
Because all molecules intrinsically expe-
rience different crystal contacts, this
allows us to deduce which parts of the
protein are rigid (Figure S2A). Within the
nine chains, all b strands and the a helix
superpose well, but some conformational
differences are present in the loops connecting b1-b2 and
b10-b11, suggesting that these loops have some degree of
flexibility.
Both the RyR1 and RyR2 NTD display the same overall fold
and can be superposed with a RMSD of 0.9 A˚ for 164 Ca atoms
(using RyR1 chain A) (Figure 1C). Even though crystal contacts
are different, the relative orientation of the a helix to the b-trefoil
core is the same for both RyR2 and the nine chains of the RyR1
asymmetric unit. This finding confirms the rigidity of the helix in
the structure.
Despite the overall similarity, a number of differences exist in
the loops connecting the various b strands. The major difference
is a 12-residue insertion in the large loop connecting helix a1with
b5 (Figure 1B). The W98 residue, which binds next to the a helix
in RyR2, is therefore not present in the RyR1 sequence and,
correspondingly, no electron density was observed in any of
the 9 RyR1 chains. An additional short 310 helix is present in
the RyR1 loop connecting b10-b11. Both loops connecting1506 Structure 17, 1505–1514, November 11, 2009 ª2009 Elsevier Ltd All rights reserved
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Structures of the RyR1 and RyR2 N-Terminal DomainsTable 1. Data Collection and Refinement Statistics
RyR2 V186M RyR2 A77V RyR2 WT RyR1 WT
Wavelength (A˚) 0.97949 0.97949 0.97934 0.97949
Resolution (A˚) 50–1.70 (1.73–1.70) 50–2.2 (2.28–2.20) 50–2.55 (2.64–2.55) 50–2.9 (3.0–2.9)
Space group I41 I41 C2 P21
Cell parameters (A˚,) a = b = 112.5 a = b = 112.2 a = 155.0 b = 39.0 a = 70.73 b = 155.71
c = 36.8 c = 36.8 c = 107.6 c = 81.61
a = b = g = 90 a = b = g = 90 a = g = 90 b = 131.8 a = g = 90 b = 110.6
No. of unique reflections 25132 (1273) 10981 (687) 15222 (945) 34226 (2509)
Rsym (%)
a 10.1 (57.7) 7.6 (38.8) 9.6 (38.1) 14.6 (40.8)
I/s(I) 20.6 (2.4) 13.9 (2.5) 19.2 (2.2) 12.37 (2.9)
Completeness (%) 99.7 (100) 93.3 (59.8) 93.6 (58.5) 92.8 (68.2)
Mosaicity () 0.52 0.78 1.0 0.45
Rcryst/Rfree (%) 20.1/24.4 22.3/27.5 22.1/28.8 27.4/32.0
No. of protein residues 175 174 349 1394
No. of water molecules 99 31 34 0
Bond lengths RMSD (A˚) 0.030 0.014 0.009 0.005
Bond angles RMSD () 2.44 1.57 1.23 0.784
Mean overall B value (A˚2) 23.1 27.7 30.3 68.0
% Residues in core/allowed regions of
Ramachandran plot
94.1/5.9 91.5/8.5 92.9/7.8 92.2/7.8
Values in parentheses refer to the highest resolution shell, where applicable.
a Rsym =ShSi j I(h,i) < I(h) > j /S hSi I(h,i), where I(h,i) is the intensity of the ithmeasurement of reflection h and < I(h) > is the average value over multiple
measurements.b1-b2 and b10-b11 display different conformations, compared
with RyR2.
Thermal Stability
In humans, particular RyR2mutations have been shown to cause
CPVT and ARVD2. At least five of these mutations are located in
the RyR2 NTD. One obvious and trivial explanation for a disease
phenotype is a general destabilization of the domain. We there-
fore measured thermal melting curves for both wild-type and
mutant NTDs using thermofluor experiments (Nettleship et al.,
2008). Wild-type RyR2 NTD has a melting temperature of
57C (Figures 2A and 2B and Table 2). None of the five point
mutations significantly alters the melting temperature. However,
there is a big discrepancy between the three RyR isoforms,
because the RyR1 NTD has a melting temperature of 46C,
significantly lower than those for RyR2 and RyR3 NTDs.
Although RyR1 and RyR2 share the same overall fold, the
stability seems to be drastically different. This correlates with
the ability of the proteins to crystallize, because RyR2 crystals
are easier to obtain and have a better diffraction quality.
However, the reasons for the difference in thermal stability are
not clear.
Structure of RyR2 Disease Mutants A77V and V186M
Because none of the disease-causing point mutations of RyR2
seems to affect the domain stability, we wondered whether
they would alter the global or local structure of the domain. To
this extent, we solved the structures of two RyR2 NTD disease
mutants, A77V and V186M, to 2.2 A˚ and 1.7 A˚, respectively,
allowing us to analyze the effects of the mutations in detail.
Superposition of both mutants with the wild-type shows that
the overall structure is conserved, with RMSD values of 0.7 A˚
for 179 (A77V) and 188 (V186M) Ca atoms. The main exception
is the b8-b9 loop (Figure S2B). Because mutants and wild-type
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Figure 2. Thermal Stability of RyR NTDs
(A) Thermofluor experiments showing thermal
melts for the NTD of RyR1 (filled squares), RyR2
(filled circles), RyR3 (open squares), and RyR2
Dexon 3 (open triangles).
(B) Measured melting temperatures for various
wild-type and mutant NTDs. *p < 105; **p < 106
(one-tail student t test). Error bars show the stan-
dard deviations. The values are shown in Table 2.
All point mutants are for the RyR2 NTD. Two tran-
sitions with separate melting temperatures were
present for RyR2 Dexon3.Structure 17, 1505–1514, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1507
Structure
Structures of the RyR1 and RyR2 N-Terminal Domainscrystallized in different space groups, this difference is likely due
to variations in crystal contacts. Indeed, the loop is involved in
crystal contacts for both A77V and V186M.
However, both positions are solvent exposed and cause
distinct local changes to the protein surface. The A77V mutation
introduces two extra methyl groups at the N-terminal end of helix
a1 (Figure 3A), exposing 33 A˚2 to the solvent. The mutation is
mostly surrounded by hydrophilic residues, including an ionic
pair between R76 and E80. Neighboring hydrophobic residues
include M81 and L73 that are in Van der Waals contact with
A77. Only small rearrangements take place in the neighboring
residues to accommodate the extra volume. The main effect of
the A77V mutation is therefore a distinct change in the surface
at the bottom of the helix (Figure 3C).
The V186 residue is present at the bottom of a deep pocket
that sits next to the N-terminal end of the a helix (Figure 3B). It
is surrounded by both hydrophilic and hydrophobic residues,
including L78 and W159, that stabilize the a helix orientation.
The V186 side chain is pointing inward but is partially exposed
to solvent. Upon mutation to methionine, there is insufficient
space for this longer side chain to point inward. The M186 there-
fore curls back toward the surface and fills up a part of the deep
pocket (Figure 3D).
Because neither mutant affects the overall structure or
stability, the only possibility remaining is that they are located
at an interface for transient or permanent domain-domain or
protein-protein interactions. The N-terminal part of the a helix
and the neighboring deep pocket therefore highlight sites
required for normal RyR function.
The b8-b9 Loop Contains Many Disease Mutations
Three other RyR2 disease mutations have been found in the
RyR2 NTD: P164S, R169Q, and R176Q. Although we have
been able to crystallize all three mutants, the diffraction limit
was too low to build reliable models. However, their ability to
crystallize in the same condition with similar crystal morphology
strongly suggests that the overall structures are not significantly
altered.
Interestingly, all threemutations map to a 16-residue long loop
connecting b8 and b9 (Figure 4A). P164 marks the beginning of
the loop, whereas R169 and R176 are part of a small network
Table 2. Melting Temperatures for RyR NTDs
Name Mean (C) Standard Deviation (C) n
RYR2 56.82 1.47 4
RYR1 45.68 1.06 6
RYR3 56.46 1.28 4
A77V 56.15 0.41 4
P164S 54.42 0.80 4
R169Q 54.00 0.57 4
R176Q 53.98 0.26 4
V186M 56.42 1.06 4
DEXON3 A 56.33 0.33 4
DEXON3 B 69.03 0.75 4
Measured melting temperatures for the NTD of the three RyR isoforms
and various RyR2 mutants. The RyR2 Dexon3 mutant displays 2 distinct
transitions (A and B).1508 Structure 17, 1505–1514, November 11, 2009 ª2009 Elsevierof ionic pairs and hydrogen bonds, which include E173 and
D179. The corresponding mutations are therefore expected to
break the ionic interactions. The b8-b9 loop has an overall posi-
tive charge in both RyR1 and RyR2 (Figure 4B; Figure S3). Inter-
estingly, a number of RyR1 disease mutations map to the same
loop. Mutations in R156 and R163 correspond to RyR2 residues
R169 and R176. The two acidic residues involved in the ionic
pairs have also been reported to cause MH or CCD (human
mutations E160G, D166N and D166G) (Rueffert et al., 2002;
Shepherd et al., 2004). The b8-b9 loop therefore seems to play
a significant role in RyR function and is likely part of a protein-
protein or domain-domain interface.
In addition to mutations in the b8-b9 loop, other RyR1 disease
mutations are more scattered across the surface, compared with
RyR2 (Figures 4C and 4D). One of these, L14R, replaces a leucine
residue, part of a hydrophobic core, by a longer arginine side chain
(Robinsonetal., 2006).Asa resultofsterichindrance, it isexpected
that such a mutation would destabilize the domain or cause
major rearrangements in the neighboring environment. However,
most of the RyR1 disease positions have some degree of surface
exposure and may, therefore, be located at interaction sites.
Delta Exon3 Mutant
An unusual cause of CPVT is the deletion of an entire exon from
the RyR2 gene (Bhuiyan et al., 2007; Marjamaa et al., 2009). The
Dexon3 mutant abolishes RyR2 residues 57–91, thus removing
a drastic portion of the RyR2 NTD structure (Figure 4C). The
structural elements that are removed include the 310 helix, b4,
the a helix, and seven residues of the following flexible loop.
b4 in particular seems to be a crucial element for maintaining
the overall fold through main chain hydrogen bonding with the
neighboring strands b1 and b5. Overall, residues in exon3 are
responsible for 36 hydrogen bonds in the structure. A likely
cause for the disease phenotype is therefore complete destabi-
lization of the domain, causing misfolding. To test this idea, we
expressed the domain in Escherichia coli like wild-type protein.
Unexpectedly, this Dexon3 RyR2 NTD is soluble and could
readily be purified. There are no indications for aggregation,
because the protein runs as a single monomeric species on a
gel filtration column (Figure S4). We next measured the thermal
stability and found the protein to have two distinct transitions
in the melting curve, one with a melting temperature similar to
the wild-type RyR2 and one with a higher temperature of 69C
(Figures 2A and 2B; Table 2). This finding suggests the presence
of two distinct subdomains within the Dexon3 mutant, including
one with improved stability. Because the structural rearrange-
ments in this mutant are likely to be very large, it is impossible
to deduce an interface from the deletion. The functional impact
of Dexon3 on intact RyR2 channels remains to be tested.
Flexible Cysteine Pairs
RyRs have been found to report on oxidative stress, and it has
been shown that cysteines play a crucial role in this process
(Durham et al., 2008; Eu et al., 2000; Eu et al., 1999; Xu et al.,
1998). Each RyR2monomer contains up to 90 cysteine residues,
and seven of these are contained within the NTD. The higher
resolution (1.7 A˚) of the RyR2 V186M mutant allows us to check
into these residues in more detail. Four individual cysteines are
arranged in two pairs that display a high degree of flexibility.Ltd All rights reserved
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Structures of the RyR1 and RyR2 N-Terminal DomainsThe first pair, consisting of C36 and C65, is located on b2 and
on the loop preceding b4 (Figure 5A). Three distinct conforma-
tions are visible for C36, including a position that points to the
solvent and a position pointing toward C65. Both residues are
conserved among RyR1–3, and mutations of the C36 counter-
part in RyR1 have been implicated in MH (Lynch et al., 1997).
A similar arrangement exists for C131 (on b6) and C158 (on the
b7-b8 loop): in this case, both adopt dual conformations pointing
either toward or away from one another (Figure 5B). C158 is
partially exposed to solvent in one conformation. This second
cysteine pair is not conserved, because C131 is present only in
RyR2. Neither of the cysteines was modeled as cystine bonds
in the V186M structure.
The hypothesis therefore arises whether any of these cyste-
ines could report on redox state by formation of a disulfide
bond or by receiving a modification. Indeed, it has been shown
that RyR1 counterpart C36 can both be S-glutathionylated and
oxidized to a disulfide in RyR1 (Aracena-Parks et al., 2006).
Whether the C131/C158 pair can undergo similar reactions in
intact RyR2 remains to be shown.
Comparison with IP3 Receptors
The b trefoil domain is structurally homologous to two domains in
the NTD of IP3 receptors (IP3R) (Bosanac et al., 2002; Bosanac
et al., 2005), suggesting a strong evolutionary relationship
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Figure 3. RyR2 A77V and V186M Mutations
Cause Distinct Changes in the Surface
(A) Superposition of RyR2 wild-type (blue) and
RyR2 A77V (orange) in the region surrounding
the mutation. Nitrogen atoms are shown as dark
blue, oxygen in red, and sulfur in yellow. The inset
shows the view (box) relative to the full domain.
(B) Superposition of RyR2 wild-type (blue) with
RyR2 V186M (brown).
(C and D) Surface representation of RyR2 wild-
type (blue) with the surface of the superposed
A77V and V186M mutations shown as a mesh.
The views are identical to the ones for the corre-
sponding Figures 3A and 3B. The A77V and
V186Mmutations alter the local surface. Numbers
shown are solvent accessible areas, with the first
number for the wild-type residue, and the second
for the mutant.
between both Ca2+ release channels. By
use of the Dali server for finding structural
homologs (Holm et al., 2008), the NTD of
the IP3 receptor (PDB 1XZZ) (Bosanac
et al., 2005) displays the largest structural
similarity. The overall fold of the b-trefoil
core is conserved, but the structures
diverge significantly outside of this core
(Figure 6). The single helix in the RyR
NTD is replaced by two helices in the
IP3R NTD, and both point in a different
direction. The RyR loop connecting
b1-b2 protrudes further away from the
core because of extended b strands,
whereas the loop b10-b11 is significantly
shortened. In addition, the loops connecting b3-b4, b7-b8, and
b8-b9 adopt very different conformations. The different loop
conformations, as well as the various amino acid substitutions,
drastically alter the overall shape and charge distribution on
the surface (Figure S3). This finding suggests that the b-trefoil
core serves as a structural template, with distinct functions
arising from the various insertions in loops connecting the
b strands.
The IP3R contains a second b-trefoil domain (Bosanac et al.,
2002), and sequence similarity strongly suggests that such a
second b-trefoil domain, immediately downstream in the
sequence, is present in RyRs as well (Bosanac et al., 2005; Sery-
sheva et al., 2005, 2008).
DISCUSSION
RyRs play a crucial role in E-C coupling of both skeletal and
cardiac muscles: they allow the regulated release of Ca2+ from
the sarcoplasmic reticulum into the cytoplasm. Their importance
is highlighted by the severe impact of sometimes subtle point
mutations in their genes. In the skeletal muscle RyR1, these
can lead to MH and CCD (Robinson et al., 2006), whereas muta-
tions in the cardiac RyR2may result in CPVT and ARVD2 (George
et al., 2007; Thomas et al., 2007). The RyRs are the largest ion
channels currently known (2.2 MDa), but the amount of atomicStructure 17, 1505–1514, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1509
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Structures of the RyR1 and RyR2 N-Terminal Domainsresolution data is very limited. This has obstructed detailed
insights into RyR function and malfunction.
In this article, we describe the crystal structures of amino
terminal domains of RyR1 and RyR2. The proteins fold as a
b-trefoil domain with an a-helical segment lining one side. The
core of the fold is similar to that found in the NTD of IP3Rs, but
significant differences outside the core change the overall shape
and charge distribution. We also determined the structures of
two RyR2 disease mutants (A77V and V186M) known to cause
CPVT and map other known mutations on the surface of both
RyR1 and RyR2.
A serious form of CPVT is caused by the removal of a 35 amino
acid stretch (exon3) in RyR2 that maps in the NTD (Bhuiyan et al.,
2007; Marjamaa et al., 2009). The more drastic phenotype asso-
ciated with this deletion correlates with the expected large
impact on the structure. In contrast, none of the point mutations
investigated so far seems to affect either the overall structure or
the stability of the domain, but instead alters a local environment.
This leaves the only possibility that these local surfaces are
involved in binding other RyR domains or auxiliary proteins.
We propose the existence of at least two important interaction
sites on the RyR NTD: one involving the loop connecting b8
and b9 and another involving the a helix with a neighboring
pocket.
Three attractive candidates can be proposed to interact with
these sites. The first includes the second mutational hot spot
K167
EXON 3
A B
C D
α1
Figure 4. Other Disease Mutations in RyR1 and RyR2
(A) Detail of the RyR2 b8-b9 loop, showing ionic pairs and hydrogen bonds. The view is from the top of Figure 1A, looking down on the loop and the a helix
N terminus. Three residues known to cause CPVT or ARVD2 are shown in green. The loop contains two other positively charged residues, K167 and K174, which
have not been found as the target of disease mutations. The K167 side chain density was not visible.
(B) Electrostatic potential of the RyR2 NTD, showing that the b8-b9 loop is positively charged. The view is from the top in Figure 1A. Missing side chains were
added to allow a more reliable surface potential calculation. The five known disease positions of the RyR2 NTD are indicated for reference, as well as two other
positively charged residues in the b8-b9 loop. The circle represents the b8-b9 loop. Numbers shown indicate the solvent accessible surface area for the side
chains of P164, R169, and R176.
(C and D) Comparison of the disease positions in RyR2 (left) and RyR1 (right) (rabbit RyR1 numbering), highlighted in green. Disease positions aremore spread out
in the RyR1 NTD. The portion deleted by the RyR2 Dexon3 mutant is highlighted in orange. The views correspond to the front view of Figure 1A.1510 Structure 17, 1505–1514, November 11, 2009 ª2009 Elsevier Ltd All rights reserved
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Structures of the RyR1 and RyR2 N-Terminal Domainsof RyR1 and RyR2. The so-called ‘‘zipper hypothesis’’ suggests
an interaction between the N-terminal and central hot spot
regions, and mutations in either region can cause destabilization
of a domain-domain interaction that is required for normal
channel function (Ikemoto and Yamamoto, 2002). A second
candidate is FKBP12. This hypothesis comes fromacombination
of modeling and docking studies, suggesting that the NTD is
located in the clamp region (Serysheva et al., 2008). In this
model, a number of mutations, including mutations in the b8-b9
loop of the NTD, are also surface exposed in the entire RyR1
structure. Because FKBP12 has been shown to map to the
same region (Samso et al., 2006; Wagenknecht et al., 1997),
the mutations could directly interfere with its binding. However,
deletion of the first 305 residues in RyR2 does not abolish
FKBP12.6 binding (Masumiya et al., 2003), so the contribution
of these sites to FKBP12.6 binding can only be minor. A third
possibility is an interaction between the NTD and the domains
immediately downstream in the sequence. In IP3Rs, the NTD is
known to affect the binding affinity of IP3 to a cleft formed by the
two downstream domains, suggesting a direct domain-domain
interaction (Bosanac et al., 2005). RyR1–3 residues 220–600
display sequence similarity with the corresponding region in
IP3Rs, and it is therefore possible that a similar domain-domain
interaction is conserved.
Although themutations in the RyR2NTD seem to cluster in two
distinct spots, a number of mutations in the RyR1 NTD are more
scattered across the surface. Although it is possible that RyR2
mutations in other regions of the NTDmay be found in the future,
one possibility is that Ca2+ handling in cardiac myocytes is more
crucial for survival than in skeletal muscle and that the corre-
sponding mutations in RyR2 would be fatal. Whether the scat-
tered mutations in RyR1 influence the domain stability or have
no long-range effects on the structure remains to be determined.
With the availability of a 9.6 A˚ cryoEM structure of an entire
RyR1 channel (Ludtke et al., 2005), the natural question arises
about the location of the NTD in the overall protein. We have per-
formed extensive docking experiments with our NTDs using the
program SITUS (Wriggers et al., 1999). The docking results vary
greatly depending on the exact method used (Figure S5). With
Laplacian filtering, the crystal structure docks in the so-called
subregion 4a, a position close the central cavity of the RyR
(Figure S5). However, elegant experiments involving the addition
of GST or GFP to N-terminal regions of RyR2 and RyR3 have
shown difference density in a region near the clamp (Liu et al.,
2001; Wang et al., 2007). These fusion proteins still retained
wild-type channel properties, suggesting that the overall impact
C36
C65
P59
L62
Q23
C158
C131
C132
Y129 Q150
L133
S187
A
B
Figure 5. Two Flexible Cysteine Pairs
(A and B) Cysteines with multiple conformations in the RyR2 V186M structure.
The surface contributed by the cysteines is taken away for clarity, showing that
some cysteines point to the solvent in distinct conformations. Select residues
are labeled for orientation. C36 is shown in 3 different conformations, whereas
both C131 and C158 have dual conformations. C65 and C132 only displayed
single conformations.
α1
α2 α1
β1-β2
β10-β11
β3-β4
β8-β9
β7-β8
Figure 6. Comparison with the IP3 Receptor NTD
Superposition of the RyR2 NTD (blue) with the IP3R NTD (green). Loops with
the most significant differences are highlighted (RyR2 labeling). The view
corresponds to the front view in Figure 1A.Structure 17, 1505–1514, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1511
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Structures of the RyR1 and RyR2 N-Terminal Domainson the folding was minimal. Because the N terminus of the
docked domain points to the central cavity, the overall length
of GST (33 A˚ between N terminus and C terminus) is insufficient
to support difference density at >90 A˚ away. Other solutions are
incompatible for the same reason (Figure S5).
Dockingwithout Laplacian filtering placesmodels in subregion
5. Although this is close to a previously proposed site (Serysheva
et al., 2005, 2008), even here caution is required, because all of
the top 5 solutions have very similar correlation values. These
solutions dock to the same site but with completely different
orientations, resulting in 90 relative rotations. Deducing the
precise location of individual amino acids within the full-length
RyR is therefore premature.
Because reliable docking into a cryoEM map depends greatly
on the relative size, it is possible that the size of the NTD (4% of
one RyR monomer) is simply too small to allow reliable docking
at this resolution. We conclude that either more experimental
restraints or higher resolution cryoEM maps are necessary to
allow a precise location and orientation of the RyR NTD.
The crystal structure of the NTD is only one step closer toward
a complete high-resolution understanding of RyR structure and
function. Besides an overall description of the protein fold, our
results highlight two distinct interaction interfaces that are
required for normal RyR function. More high-resolution struc-
tures will be necessary to increase our understanding of the
largest ion channel currently known.
It should be noted that, during preparation of this manuscript,
coordinates for a RyR1 NTD crystal structure were deposited in
the PDB database by F. Amador and co-workers (PDB ID
3HSM), and the results were recently published (Amador et al.,
2009). Their structure is very similar to our independently solved
RyR1 NTD structure. However, no structures of the RyR2 NTD or
any disease mutants had been reported by this group. One
finding of these authors was that the b8-b9 loop forms a muta-
tional ‘‘hot spot,’’ which corresponds to one of our two proposed
interaction sites.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification
Rabbit RyR1 (residues 9–205), mouse RyR2 (residues 1–217), and human
RyR3 (residues 10–207) were cloned into a modified pET28 vector containing,
in tandem, a His-tag, MBP, and a TEV cleavage site, followed by the construct
of interest (Van Petegem et al., 2004). Mutations were made using the Quik-
change protocol (Stratagene). Proteins were expressed at 30C or 37C in
E. coli Rosetta (DE3) pLacI strains (Novagen), induced at OD600 of 0.6 with
0.2 mM IPTG, and were grown for 4 more hours prior to harvesting. Cells
were lysed via sonication in buffer A (250 mM KCl and 10 mM HEPES [pH
7.4]) with 25 mg/ml DNaseI and 25 mg/ml lysozyme, were applied to a PorosMC
column (Tosoh Biosep), were washed with 5 column volumes (CV) of buffer A
and 5 CV of buffer A plus 10 mM imidazole, and were eluted with buffer B
(250 mM KCl plus 500 mM imidazole [pH 7.4]). The protein was dialyzed
overnight against buffer A and was cleaved simultaneously with recombinant
TEV protease. The samples were then run on another PorosMC column in
buffer A, and the flowthrough was collected and dialyzed against buffer C
(10 mM KCl plus 20 mM Tris-Cl [pH 8.8]), applied to a ResourceQ column
(GE Healthcare), and eluted with a gradient from 0% to 40% buffer D (1 M
KCl plus 20 mM Tris-Cl [pH 8.8]). Finally, the samples were run on a Super-
dex200 (GE Healthcare) gel filtration column in buffer A. The protein samples
were exchanged to 10 mM KCl plus 5 mM HEPES (pH 7.4), concentrated to
10–20 mg/ml using Amicon concentrators (10K MWCO; Millipore), and stored
at 80C.1512 Structure 17, 1505–1514, November 11, 2009 ª2009 ElsevierCrystallization and Data Collection
All crystals were obtained by hanging drop vapor diffusion. Wild-type RyR2
NTD crystals appeared in 0.5–1.5M malonate (pH 4.0). The best crystals for
RyR2 A77V and V186M were obtained in 0.1 M malonate (pH 4.6–4.9) plus
5%–20% saturated (NH4)2SO4. RyR1 NTD crystals appeared in 0.1 M Bis-
Tris (pH 7.0) plus 15%–25% PEG3350. Crystals were transferred to paratone
oil and flash-frozen in liquid N2 prior to data collection. The datasets were
collected at the Stanford Synchrotron Radiation Lightsource (SSRL) beamline
11-1 and the Canadian Light Source (CLS) beamline 08ID-1, and were pro-
cessed using the HKL2000 package (HKL Research). Data collection statistics
are available in Table 1.
Structure Solution and Refinement
A molecular replacement search model was designed, consisting of a minimal
b-trefoil domain (IP3R NTD, PDB ID 1XZZ), stripped from all loops and with all
side chains truncated to alanine. Molecular replacement was performed with
Phaser (McCoy et al., 2007). Because of the poor initial phasing power of
the search model, we used the data set with the highest diffraction (1.7 A˚ for
RyR2 V186M) and obtained an initial model via autobuilding procedures imple-
mented in ARP/wARP (Langer et al., 2008). The model was completed by
successive rounds of manual model building in COOT (Emsley and Cowtan,
2004) and refinement with REFMAC5.5 (Murshudov et al., 1997). A simulated
annealing composite omit map was calculated with CNS (Brunger et al., 1998)
to verify the absence of residual model bias (Figure S1A). The RyR2 WT and
A77V structures were solved by using the refined V186M structure as a molec-
ular replacement model. For RyR1, the molecular replacement model con-
sisted of the RyR2 NTD structure with all nonidentical amino acids truncated
to alanine. Side chains with missing densities were not modeled but were
included in the electrostatic calculations with APBS (Baker et al., 2001). The
number of molecules in the asymmetric unit are two (RyR2 WT), one (A77V
and V186M), and nine (RyR1). One chain in the RyR1 structure has poor elec-
tron density and was only modeled partially (chain I).
The final refinement statistics can be seen in Table 1. The slightly elevated R
and Rfree factors are most likely due to the presence of a long loop (residues
88–109) for which there was significant difference density but that could not be
modeled (Figure S1B). The exception is W98, which we modeled inside a
hydrophobic pocket for the following reasons: the corresponding density
shows up for both wild-type chains and both point mutants in weighted differ-
ence maps and a composite map; its location in the middle of the flexible loop
places it at the expected position; the density is especially clear for the 1.7 A˚
V186M data, with the distinct features of a tryptophan side chain containing
a hole in the aromatic ring (Figure S1C); its location in a hydrophobic pocket
is a preferred chemical location; and the electron density at this site does
not show up for any of the 9 RyR1 chains that do not have a tryptophan in
this loop. All structure figures were prepared using PYMOL (DeLano Scientific,
San Carlos).
Thermal Melting Curves
The protein melting curves were measured by means of thermofluor experi-
ments (Nettleship et al., 2008). Samples for melting curves contained 50 ml
of 0.2 mg/ml protein and 13 SYPRO Orange solution (Invitrogen) using manu-
facturer’s instructions. The melts were obtained in a DNA engine opticon
2 real-time PCR machine (BIORAD), using the SYBR green filter option. The
temperature was changed from 20C to 95C in 0.5C steps. At every step,
the temperature was kept constant for 15 s. The melting temperatures were
obtained by taking the maxima of the first derivative of the melting curve
(RyR2 Dexon3) or by taking the midpoint of each transition (all other samples).
ACCESSION NUMBERS
Coordinates of the structures have been deposited in the RCSB database with
PDB accession codes 3IM5, 3IM6, 3IM7, and 3ILA.
SUPPLEMENTAL DATA
Supplemental data include five figures and can be found with this article online
at http://www.cell.com/structure/supplemental/S0969-2126(09)00373-6.Ltd All rights reserved
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